Products & ReviewClinical Diagnostics

LumiraDx Platform

Next-generation point of care diagnostic platform - Next-generation microfluidic technology on the LumiraDx Platform enables lab-comparable performance across a broad menu of diagnostic assays.

LumiraDx

The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our  Product Directory.

Ease of Use
After Sales Service
Value for Money
Be the first to leave a review
Description

Broad menu of lab comparable results on a single, portable diagnostic point-of-care platform

Currently offering CRP, D-Dimer, HbA1c, INR, NT-proBNP, SARS-CoV-2 Antigen and Antibody test capabilities, with a pipeline of over 30 tests across a range of assay technologies including enzyme, immunoassay, molecular and electrolyte assays. All carried out on one, easy to use device.

  • Multiple tests on a single platform
  • One simple, intuitive test workflow
  • Small sample volumes, including capillary blood
  • Portable instrument, seamless connectivity
  • Room temperature storage of test strips
Application NoteClinical Diagnostics

The role of rapid diagnostics in tackling antimicrobial resistance

This application note contains key insights on the current policy landscape and practical challenges on the frontline of care and the role of rapid diagnostics in relation to tackling antimicrobial resistance (AMR), with an emphasis on identifying key barriers and challenges in relation to the uptake of rapid diagnostics.


Application NoteClinical Diagnostics

Performance evaluation of a rapid multiplex point-of-care microfluidic immunofluorescence assay for the detection of SARS-CoV-2 Antigen and Flu A/B

In this application note, the performance of the LumiraDx SARS-CoV-2 & Flu A/B Test was evaluated versus RT-PCR using anterior nasal swabs from symptomatic patients. The LumiraDx SARS-CoV-2 & Flu A/B Test is an automated, rapid, microfluidic immunofluorescence assay for use with the LumiraDx Platform, for near-patient testing, intended for the qualitative detection and differentiation of SARS-CoV-2, Influenza A and/or Influenza B viral antigens from nasal swab samples.



LumiraDx: Transforming healthcare at the point of need

In this video, discover how the LumiraDx platform was designed to fill the need for a next-generation testing technology that offers both performance and speed. Hear how the LumiraDx platform is designed to run assays across common health conditions including infectious disease, cardiovascular disease, diabetes, and coagulation disorders.


LumiraDx: Transforming community-based healthcare

In this video, learn more about LumiraDx and its next-generation point-of-care diagnostic platform which combines a small, portable Instrument; microfluidic Test Strip; simple, standardized workflow; and seamless, secure digital connectivity to cloud and hospital IT systems.





LumiraDx Platform

In this video, LumiraDx introduces the LumiraDx Platform, with next-generation microfluidic technology which enables lab-comparable performance across a broad menu of diagnostic assays.


Product Overview

Links